12:46:59 PM: Hi from Berkeley, California- I’m at the Open Science Summit http://bit.ly/b4NRq1. Tweets on open innovation and drug discovery to follow!
12:51:12 PM: Aiden Hollis of Yale’s Health Impact Fund is first http://bit.ly/Msd2N.
12:53:00 PM: Fund aims to reward pharma co’s based on drugs’ health impact, if companies agree to sell at cost. Financing would come from government.
12:58:32 PM: Health Impact Fund is planning a pilot project- but companies, countries, and drugs to be involved weren’t specified. #oss2010
12:59:54 PM: RT @uaem: Jamie Love, from here: http://bit.ly/cKAEcn talking re: prizes to de-link cost of R&D from the cost of the final product #oss2010
1:05:11 PM: Love is again talking about rewarding a drug’s ‘health impact’. This is nebulous to me. How do you measure this impact a priori? #oss2010
1:15:04 PM: RT @OrthoNormalRuss: @carmendrahl when someone makes such vague assertions, they call them “details to be hashed out later” by some agency
1:16:56 PM: Love’s talk was rich in econ-speak but vague on details- more may be found here: http://bit.ly/9UGbPL in a comment sent to WHO #oss2010
1:27:35 PM: Columbia U GS @OrthoNormalRuss is sad this session didn’t really deliver novel alternatives for R&D funding- same old gov’t $$ arguments.
1:39:15 PM: If you’d like to follow the Summit live you can at http://bit.ly/d2t4JC #oss2010 (Thx to Lisa Green, Creative Commons @boudicca for link)
1:48:19 PM: Next session is called ‘Cure Entrepreneurs’: first speaker is Scott Johnson, prez of Myelin Repair Foundation. http://bit.ly/7VK9K
1:52:03 PM: RT @mrgunn: Patient activism session up now. These folks tend to be passionate, so tune in now. #oss2010
1:54:46 PM: Johnson is describing the gap that exists between basic academic research, and research in pharma that leads to medications.
1:58:33 PM: Johnson sees nonprofits like Myelin Found. as a shepherd-herd molecules through R&D through the approval process.
2:04:34 PM: Myelin Foundation currently funding ~45 scientists. Universities own any patents, foundation has exclusive development rights.
2:06:22 PM: Johnson says it’s hard to get federal funding for developing tools and models for myelin repair research. Really? #oss2010
2:08:54 PM: Johnson-1st patent from these efforts awarded in 2008. A partnership with a pharma company (unnamed) has also been initiated.
2:11:40 PM: Myelin repair drugs would treat multiple sclerosis: read @lisamjarvis #CENews story on race to new MS drugs http://bit.ly/9Iaz7N #oss2010
2:14:18 PM: Next: Craig Benson, founder of foundation to accelerate treatments for Batten Disease, rare neurodegenerative disease http://bit.ly/9eM05S
2:19:38 PM: Among Beyond Batten’s goals: developing accessible screens to test for carriers of orphan diseases like Batten
2:21:09 PM: Benson has a daughter with Batten Disease. Johnson has multiple sclerosis.
2:28:01 PM: Benson-Foundation dev’d a universal carrier screening test for 450 orphan diseases for under $500. Product launch planned for 2011 #oss2010
2:34:12 PM: More details on Benson and Beyond Batten in a Mar.2010 Bio-IT World article: http://bit.ly/9i1eSj #oss2010
2:37:50 PM: Now Beth Anne Baber, cancer bio researcher, mom of pediatric cancer patient, cofounder of ped. cancer foundation http://bit.ly/4WY0MH
2:41:36 PM: Conor Institute Model: ID industry partner(s), foundation provides human capital in onsite labs. Multiple partners in different expertises
3:13:46 PM: We’re breaking for lunch now- will start up again in about 1/2 hour.
4:04:22 PM: Back from lunch. There was some discussion there about how open the morning sessions truly were, if connected to a patent model.
4:13:21 PM: schedule change: Instead of J. Izant of Sage Bionetworks, Nick Shockey @R2RC, Right to Research Coalition speaking on open access journals.
4:19:02 PM: Joerg Kurt Wegner (@joergkurtwegner), a scientist at Tibotec, asked me “What was the conclusion, if any, of the linkage to a patent system?”
4:20:32 PM: I told him I don’t think a consensus was reached- the companies seem to want patents to ensure ability to commercialize.
4:21:36 PM: More than a few of the speakers at the conference yesterday were arguing the opposite. Surprised this hasn’t come up more in Q&A’s.
4:29:58 PM: Jonathan Izant of Sage Bionetworks @sagebio http://bit.ly/9C6CqS now speaking.
4:31:43 PM: Sage is a nonprofit that wants to build an open-source spot where scientists can share genomic data to better understand disease biology.
4:43:32 PM: Izant’s talking about challenges- developing data standards and accessible data formats, obstacles to sharing data btw academic labs
4:46:43 PM: Barry Bunin, CEO of Collaborative Drug Discovery and PhD in chemistry from UC Berkeley, is next. http://bit.ly/au1bqp
4:49:08 PM: Bunin-CDD wants to offer a few paths- let companies be open when they want to be open-and share data in a closed fashion at other times
4:53:13 PM: Bunin opens w/case study- collaborative effort that revealed known, approved drugs that reverse resistance to malaria drug chloroquine
4:55:33 PM: Bunin- CDD started largely academic but now is ~50-50 academe-industry: list of who benefits here: http://bit.ly/acFOv0 #oss2010
5:02:12 PM: More players in pharma’s neglected-disease data sharing: http://bit.ly/9tmfnb EuropeanBioinformatics Institute, Nat’l Lib Med, MMV #oss2010
5:09:02 PM: Now Andrew Hessel, founder of Pink Army, on bringing the open source development model to breast cancer R&D http://pinkarmy.org/
5:18:07 PM: Hessel’s contrasting combating bacteria-with great evolutionary distance: vs combating cancer:small evo distance #oss2010
5:21:11 PM: Hessel- we need more specific approaches. I say-what about all the cool stuff going on with sugar metabolism? http://bit.ly/bBHm1P #oss2010
5:40:45 PM: Q&A w/Bunin, Izant, and Hessel has begun: audience member says citing, giving credit w/in open drug development is key
5:49:15 PM: Hessel is getting questions about Pink army’s goal- 1 drug to 1 patient.
5:52:12 PM: Asked if the regulatory environment is changing to allow such a thing to take place. Short answer seems to be not yet.
5:57:44 PM: That concludes the portion of the program on open science and drug discovery. I’ll still be tweeting but I’ll be signing off liveblog now.
Leave a Reply